The HER2 protooncogene encodes a 185-kD transmembrane phosphoglycoprotein, human epidermal growth factor receptor 2 (p185u~Rz), whose amplified expression on the cell surface can lead to malignant transformation. Overexpression of HER2/p185 urR2 is strongly correlated with progression of human ovarian and breast carcinomas. Recent studies have shown that human T cells can be targeted with bispecific antibody to react against human tumor cells in vitro. We have developed a bispecific F(ab')2 antibody molecule consisting of a humanized arm with a specificity to p185 ursz linked to another arm derived from a murine anti-CD3 monoclonal antibody that we have cloned from UCHT1 hybridoma. The antigen-binding loops for the anti-CD3 were installed in the context of human variable region framework residues, thus forming a fully humanized BsF(ab')2 fragment. Additional variants were produced by replacement of amino acid residues located in light chain complementarity determining region 2 and heavy chain framework region 3 of the humanized anti-CD3 arm. Flow cytometry analysis showed that the bispecific F(ab')2 molecules can bind specifically to cells overexpressing p185 urR2 and to normal human peripheral blood mononuclear cells bearing the CD3 surface marker. In additional experiments, the presence of bispecific F(ab')2 caused up to fourfold enhancement in the cytotoxic activities of human T cells against tumor cells overexpressing p185 n~R2 as determined by a SlCr release assay. These bispecific molecules have a potential use as therapeutic agents for the treatment of cancer. ecent studies have revealed an association between overexpression of the HER2 protooncogene and the progression of breast and ovarian carcinomas accompanied by worsened clinical outcome (1-3). HER2 encodes a transmembrane phosphoglycoprotein receptor tyrosine kinase with an approximate molecular weight of 185,000 (p185 u~2) whose amplified expression can lead to malignant transformation as determined in soft agar assays and in nude mice models (4, 5). Thus, HER2 may play a crucial role in the tumorigenesis of breast and ovarian carcinomas in humans (2). Of relevance, cells overexpressing HER2/p185 ur~ exhibit more resistance to cytotoxic effects of monocytes and TNF-ot, a cytokine that has direct antitumor activities and is thought to mediate immune cell killing of tumor cells (5).
Summary
The HER2 protooncogene encodes a 185-kD transmembrane phosphoglycoprotein, human epidermal growth factor receptor 2 (p185u~Rz), whose amplified expression on the cell surface can lead to malignant transformation. Overexpression of HER2/p185 urR2 is strongly correlated with progression of human ovarian and breast carcinomas. Recent studies have shown that human T cells can be targeted with bispecific antibody to react against human tumor cells in vitro. We have developed a bispecific F(ab')2 antibody molecule consisting of a humanized arm with a specificity to p185 ursz linked to another arm derived from a murine anti-CD3 monoclonal antibody that we have cloned from UCHT1 hybridoma. The antigen-binding loops for the anti-CD3 were installed in the context of human variable region framework residues, thus forming a fully humanized BsF(ab')2 fragment. Additional variants were produced by replacement of amino acid residues located in light chain complementarity determining region 2 and heavy chain framework region 3 of the humanized anti-CD3 arm. Flow cytometry analysis showed that the bispecific F(ab')2 molecules can bind specifically to cells overexpressing p185 urR2 and to normal human peripheral blood mononuclear cells bearing the CD3 surface marker. In additional experiments, the presence of bispecific F(ab')2 caused up to fourfold enhancement in the cytotoxic activities of human T cells against tumor cells overexpressing p185 n~R2 as determined by a SlCr release assay. These bispecific molecules have a potential use as therapeutic agents for the treatment of cancer. ecent studies have revealed an association between overexpression of the HER2 protooncogene and the progression of breast and ovarian carcinomas accompanied by worsened clinical outcome (1) (2) (3) . HER2 encodes a transmembrane phosphoglycoprotein receptor tyrosine kinase with an approximate molecular weight of 185,000 (p185 u~2) whose amplified expression can lead to malignant transformation as determined in soft agar assays and in nude mice models (4, 5) . Thus, HER2 may play a crucial role in the tumorigenesis of breast and ovarian carcinomas in humans (2) . Of relevance, cells overexpressing HER2/p185 ur~ exhibit more resistance to cytotoxic effects of monocytes and TNF-ot, a cytokine that has direct antitumor activities and is thought to mediate immune cell killing of tumor cells (5) .
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Bispecific mAbs (BsmAbs) with dual specificities for tumorassociated antigens on tumor cells and for surface markers on immune effector cells have been described (6, 7) . These BsmAbs have been shown to be effective in directing and triggering effector cells to kill tumor cell targets (8) . One approach to produce BsmAb involves the fusion of two mAbproducing hybridomas to form quadromas that secrete BsmAb in addition to undesirable chain combinations including parental mAbs. Another approach utilizes directed chemical coupling of Fab' fragments from two different mAbs to assemble a BsmAb with the desired specificities (9) . Limitations associated with such approaches include the ability of rodent-derived BsmAb to elicit immune response in humans. To this end, genetic engineering techniques have been applied to production of less immunogenic "humanized" antibodies (10, 11 ). Recently~ we have described the humanization of murine mAb.4D5 (mumAb4D5), which is directed against the extracellular domain (ECD) of p185 ur~ The humanized (hu) antibody, humAb4D5-8, consists of the antigen-binding hypervariable regions from the murine parent mAb together with human variable region framework residues and constant domains (12) .
In this report, we describe the production of humanized BsF(ab')2 with specificities toward the extracellular domain of p185 uER2, and the human T cell surface marker CD3. Thus, one arm is humAb4D5-8 and the other a humanized version of murine anti-CD3 mAb, UCHT1. Our approach involved separate Escherichia coli secretion of each Fab' followed by directed chemical coupling reaction in vitro to form the BsF(ab')2 fragment. Data are presented demonstrating the biological properties of these BsF(ab')2 molecules, including the specific binding to cells overexpressing p185 uER2 and to normal human T cells; and their ability to trigger the lytic activity of human CTL against breast tumor targets.
Materials and Methods
Cloning of Anti-CD3 Variable Region Genes. The mumAb anti-CD3-producing bybridoma UCHTI (13) was used for extraction of mR.NA (14) . The genes encoding mumAb anti-CD3 variable domains were isolated by PCR amplification of mRNA as described (15) . NH2-terminal sequencing of mumAb anti-CD3 light and heavy chains was used to design the sense strand PCR primers, whereas the antisense PCR primers were based upon consensus sequences of murine FK residues (16) incorporating unique restriction sites for directional cloning shown by underlining and listed after the sequences: VL sense, 5' TTTAACGCGTACGCT-GACATCCAGATGACC CAGACCACCTCCTCCCTGTCTGC-CTCCC~GAY3', M/uI; VL antisense, 5' TTTGCATGCGT-C'ITIGGC~TAGAAGTTGTTCAAGAAGCA Y, SphI; V. sense, 5' AACGCGTACGCTGAKGTSCAILCTSCARCARTC 3', MluI and V. antisense 5 ~ GGCAGAGATCCA~CCGTGGATA-GACAGATGG 3', A~I; where Y = T or C, R = A or G, and S = C. For each variable domain, the products from two independent PCR reactions were cloned into the pUCllg-based phagemid pAK2 (12) , and a total of at least five clones was sequenced by the dideoxy method (17) .
Molecular Modeling and Construction of Humanized mAb Anti-CD3 Genes. Humanization of mumAb anti-CD3 by installing CDK residues from this murine antibody into the context of consensus human FR sequences was performed as previously described for mumAb4D5-8 (12) . Briefly, mumAb anti-CD3 was humanized by judicious recruitment of corresponding CDR residues and a few FK residues into the humAb4DS-8 molecule. Differences between mumAb anti-CD3 and the human consensus FR residues (see Fig.  1 ) were individually modeled to investigate their possible influence on CDR conformation and/or binding to CD3. Genes encoding humAb anti-CD3 variant 1 V~ and V, domains were assembled by gene conversion mutagenesis of corresponding humAb4D5 gene segments cloned in pUC119 (12) using 246-met and 283-mer preassembled olignnucleotides, respectively. Briefly, sets of four contiguous oligonucleotides were designed to create humAb anti-CD3 V. and VL utilizing codons commonly found in highly expressed E. coli genes (see Fig. 1 ). These oligonucleotides are 54-85 residues in length, contain 7-17 mismatches to the humAb4D5 templates, and are constrained to have eight or nine perfectly matched residues at each end to promote ef~cient annealing and ligation of adjacent oligonucleotides. The sets of oligonucleotides were phosphoryhted, annealed to corresponding templates, and ligated. Full-length oligomers were isolated after electrophoresis on a 6% acrylamide sequencing gel and then used for an efficient mutagenesis procedure (12) . Clones precisely encoding mumAb anti-CD3 V. and VL (Fig. 1) were identified by nucleotide sequencing (17) .
Additional humAb anti-CD3 variants were designed in which one or more mumAb anti-CD3 residues were replaced by their human counterparts in order to test their role in antigen binding, namely V. K73D and/or VL R53S (a single letter code for the original amino acid followed by the residue number according to Kabbat et al. [16] and then the amino acid replacement). The murine V. residue, K73, is located in a loop that is close to heavy chain CDILs H1 and H2 (Fig. 2) , and might be involved in antigen binding. In contrast, our humAbs usually contain an aspartate at this position as they are derived from a consensus sequence of V, group III, which is the most abundant human group in the compilation of Kabat et al. (16) . V~ residue 53 is an arginine in mumAbantiCD3 that is located towards the COOH terminus of CDR L2 and may be able to reach up and assist in antigen binding while also interacting with the phenyl ring of V~ Y50 (see Fig. 2 ). In our humAbs, this residue is normally a serine derived from a consensus sequence of V~ g subgroup I, which is the most abundant human light chain subgroup (16) . These additional variants were generated by an ef~cient site-directed mutagenesis method (18) using the oligonucleotides:
where an asterisk indicates a mismatch and unique restriction sites introduced are underlined.
Fa~ Fragment Expression for humAb4D5-8 and Anti-CD3 raAb Variants. We previously described the vector, pAK19, for the cosecretion of humAb4D5 light chain and heavy chain Fd' fragments from E. coli (19) , which is available upon request to the authors. Briefly, the Fab' expression unit is dicistronic with both chains under the transcriptional control of theph0A promoter (20) , ends with the bacteriophage X to transcriptional terminator (21) and is cloned between the EcoR/and HindlIl site of pBR322 (22) . The humanized VL and V. domains (12) are precisely fused on their 5' ends to a gene segment encoding the heat-stable enterotoxin II signal sequence (23) and on their 3' side to human ~1 (C0 (24) and IgG1 (C.1) (25), followed by the hinge sequence CysAlaAla (19) constant domains, respectively. Chimeric and humanized versions of mumAb anti-CD3 Fab' were constructed by precisely replacing gene segments encoding humAb4D5-8 VL and V. in pAK19 with appropriate genes encoding mAb anti-CD3 VL and V. variants by subdoning (26) and site-directed mutageuesis as described (12) . Fab' fragments were expressed in a phage-resistant derivative of E. coli strain KV308 (27) at high cell density in the fermentor as previously described (19) .
Constrac~n of Bispecific F(a~/)2 Fragments.
Intact and functionary active humAb45D5-8 Fab' has been recovered from E. coli fermentation pastes with the unpaired hinge cysteine present mainly (75-90%) in the labile-free thiol form (Fab'-SH) by affinity purification using Streptococcal protein G at pH '~5 in the presence of 10 mM EDTA (19) . The anti-CD3 mAb Fab'-SH was recovered by similar procedures and reacted with 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) (28) to form the thionitrobenzoate derivative (Fab'-TNB). The construction of bispecific (Bs) F(ab')2 fragments was completed by directed chemical coupling (29) of Fab'-TNB derivative of the anti-CD3 mAb with humAb4D5-8 Fab'-SH. Equimolar quantities of Fab'-TNB (by TNB content) and Pab'-SH (by SH content) were coupled at a combined concentration of ~>0.25 mg/ml in the presence of 100 mM Tris-HC1, pH 7.5, and 10 mM EDTA for 1 h at 37~ The resulting BsF(ab')2 fragments were isolated from the coupling reaction by S100-HK gel filtration (Pharmada Fine Chemicals, Piscataway, NJ) in the presence of PBS. The BsF(ab')2 samples were passed through a sterile 0.2-/xm filter and stored either at 4~ or flash frozen in liquid nitrogen and stored at -70~ until used.
Cell Lines. Breast The cells were grown in an equal mixture of DME and F12 Ham (Gibco Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated (30 min, 56~ FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 #g/ml Streptomycin (Gibco Laboratories) (complete medium).
Human Cytotoxic Lymphocytes. Blood of normal volunteers was drawn into heparinized syringes, mixed with an equal volume of PBS layered onto Ficoll/Hypaque gradient (specific gravity 1.077) and centrifuged for 45 min at 400 g. The separated band of PBMC was aspirated, washed three times in ice cold PBS, and resuspended in complete medium. PBMC were depleted of monocytes by adherence to plastic for 60 min in 100 x 60-ram plates (Costar Corp., Cambridge, MA) at 37~ CO2. Nonadherent PBMC were activated by incubation in the presence of 11.,2 for 24 h and were used as effector CTL against SlCr-labeled tumor targets in a 4-h StCr release cytotoxicity assay (30) . In some experiments, effector CTLs were tested against targets prepared by PHA blastogenic stimulation of PBMC obtained from the same donor of effector calls as detailed previously (30) .
Cytotoxicity Assay. SK-BR-3, or NR6/10 cells (3 x 106/ml), were labeled with 150 #Ci of NazSlCrO4 (Amersham Corp., Arlington Heights, IL) for 60 min, washed, adjusted to 104 cells/ 50 #1 of complete medium, and dispensed into round-bottomed microtiter plates containing quadruplicates of various numbers of effector CTLs in 100 #1 of complete medium. Various concentrations of Bs F(ab')2 fragments alone or mixed with p185 m~ ECD were then added in 50-#1 volumes (final volume per well = 200 /~1) and the plates were incubated at 37~ CO2. After 4 h, the supernatants were harvested (Skatron Inc., Sterling, VA), and their radioactivity was determined using a gamma counter (Micromedic Systems, Inc., Horsham, PA). Percent cytotoxicity was calculated as follows: percent cytotoxicity = 100x (A -B)/(C -B); where A represents the mean counts per minute (cpm) in test supernatants, B represents the mean cpm in supernatants of targets alone (spontaneous S~Cr release), and C represents the mean cpm in supernatants of targets lysed with 1% SDS (maximum SlCr release).
Flow Cytometric Analysis of BsF(ab')2 Binding. Aliquots of 106
cells were mixed in either PBS + 1% FCS (PBS + 1%) or PBS + 1% containing chimeric or humanized BsF(ab')2 (10 #g/ml). The cells were incubated on ice for 45 rain, washed twice in PBS + 1%, and stained with fluorescein-labeled goat anti-human Fab (Tago Inc., Burlingame, CA) for 45 min. In experiments involving the blocking of BsF(ab')2 binding, cells were treated with BsF(ab')2 antibody in the absence or presence of soluble p185 sea2 extracellular domain preparation of the p185 n~e2, or rCD4 receptor as a negative control (50 #g/ml) before addition of the fluorescein-hbded reagent. The stained cells were washed four times in ice-cold PBS + 1% and analyzed using a FACS | (Becton Dickinson & Co., Mountain View, CA). 10 s cells were acquired by list mode, and measurements were performed on a single-cell basis and were displayed as frequency distribution histograms. Dead cells and debris were gated out of the analysis on the basis of forward light scatter.
Results
Humanization of mumAb Anti-CD3 V~ and Vs. The gene segments encoding mumAb anti-CD3 V~ and V, were first cloned by PCR from the corresponding hybridoma, UCHTI, and sequenced (Fig. 1) . Next, the deduced variable domain amino acid sequences and molecular modeling were used to design a humanized variant of mumAb anti-CD3 (vl) (Fig.  2) as previously described for mumAb4D5 (12) . Corresponding genes for humanized anti-CD3 vl were created by gene conversion mutagenesis (12) starting from humAb4D5 genes and using long preassembled oligonucleotides (Fig. 1) . As detailed in Materials and Methods, further humanized anti-CD3 variants were created by replacement of two additional residues from mumAb anti-CD3 with their human counterparts to investigate their role in antigen binding. Thus, humanized anti-CD3 v2 and v3 incorporate the replacements V. K73D and VL R53S, respectively, whereas v4 includes both of these changes.
Preparation of BsF(at02 Fragments. We have previously described the secretion of functional humAb4D5 Fab' fragments from E. coli at titers of 1-2 g/liter as judged by antigen-binding ELISA after affinity purification on Staphylococcal protein A (19) . Chimeric and humanized versions of anti-CD3 were expressed in the same vector (pAK19) at titers of up to 400 mg/liter as judged by total Ig ELISA. Fab' fragments were recovered from E. coli cell pastes with the hinge cysteine present mainly (75-90%) as the free thiol (Fab'-SH). This was achieved by affinity purification of Fab'-SH on Streptococcal protein G at pH 5 to maintain the thiol in the less reactive protonated form and in the presence of EDTA to chehte metal ions capable of catalyzing disulfide bond formation. Bs F(ab')2 fragments were then constructed by directed chemical coupling in vitro of humAb4D5 Fab' and anti-CD3 mAb Fab' using the procedure of Brennan et al. (29) . One arm of the BsF(ab')2 was always the most potent humanized anti-p185 ur~z variant previously identified (humAb4DS-8), which binds p185 ur-~2 ECD threefold more tightly than the murine parent Ab (12) . The other arm was either a chimeric or humanized variant of the anti-CD3 mAb. Henceforth in this text the term chimeric BsF(ab')2 refers to a molectfle in which one arm is the humanized anti-p185 ue~ and the other arm is the chimeric anti-CD3; and the terms BsF(ab')2 vl, v2, v3, and v4 describe a molecule in which one arm is humanized antip185 HEa2 and the other arm is humanized anti-CD3 variant 1, 2, 3, and 4, respectively (Fig. 2) . TCCGAAACTAC TGAT TTAC TATACCTCCCGCCTGGAGTC  TGGAGTCCCTTC T CGC T TC TCTGGTTCTGGT TC TGGGACGGATTACAC TC TGACCATCAGCAGTCTGCAACCGGAAGAC  -- (Fig. 4, left) . In contrast, there were significant differences in the binding efficiency of these molecules to human CTLs. Chimeric BsF(ab')2 antibody was most effective in binding (Fig. 4, right, B) followed by BsF(ab')2 vl (C), v3 (E), and v2 (D), as reflected by different peaks of fluorescence intensities; BsF(ab')2 v4 antibody was least effective in its binding to cytotoxic lymphocytes (F). Thus, the manipulation of the anti-CD3 arm of the BsF(ab')2 fragments profoundly altered its binding to lymphocytes.
Specific Binding of BsF(aP)2 Fragments to
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Targeting of Tumor Cell Killing by BsF(ab')2 Fragments.
The killing of cells overexpressing p185 hER2 (NR6/10) or breast tumor cells SK-BR-3 by activated human cytotoxic lymphocytes was examined in the presence of various doses of BsF(ab')z, and preliminary results indicated that as little as 10 ng/ml of chimeric BsF(ab')z or BsF(ab')z vl was sufficient to cause maximal enhancement in the cytotoxic activity of CTLs. This dose (10 ng/ml) was used to compare the ability of chimeric BsF(ab')2 to enhance the cytotoxic activity of CTL with each of the BsF(ab')2 variant molecules. The addition of 10 ng/ml of chimeric BsF(ab')z, BsF(ab')2 vl, or v3 caused a three-to fourfold enhancement of the cytotoxicity of CTLs against SK-BR-3 breast tumor cells (Fig. 5 A) whereas the presence of BsF(ab')2 v2 or v4 resulted in no enhancement above control values. Enhancement caused by Fluorosoonce Intemil~ (log) Figure 3 . Flow cytometric analysis of NR6/10 cells bound to chimeric BsF(ab')2. Cells were incubated with PBS (A), chimeric BsF(ab')2 (B), chimeric BsF(ab')2 mixed with p185 usR2 ECD (C), or chimeric BsF(ab')2 mixed with recombinant CD4 (D) before staining with goat anti-human F(ab')2-FITC (conjugated Ab).
BsF(ab')2 vl was reversed by the addition of p185 usR2 ECD to the assay mixture (Fig. 5 A) demonstrating the specificity of antibody action. The results from an independent experiment (Fig. 5 B) demonstrate that 10 ng/ml of BsF(ab')2 vl consistently enhanced the function of CTLs against SK-BR-3 targets known to overexpress p185 HrPa (64 pg//~g cell protein; 3, 12) but had no effect on the cytotoxicity of CTLs against MDA-MB-175 targets, which express low to moderate levels of p185 urR2 (7.7 pg//~g cell protein; 3, 12). These results demonstrate the efficacy of chimeric BsF(ab')2 vl, and v3 in directing cytotoxic lymphocytes to kill breast tumor targets overexpressing p185 u~R2 but not targets with low p185 HrR2 expression. The cytotoxicity data (Fig. 5 A) correlate well with FACS | binding data (Fig. 4) in that BsF(ab')2 v2 and v4, which were inefficient in binding to cytotoxic lymphocytes, failed to direct tumor cell killing in the cytotoxicity assay. None of these BsF(ab')2 molecules affected the cytotoxic activity of human CTL when tested against PHAo induced blastogenic targets derived from the same donor, demonstrating that these BsF(ab')z do not mediate the lysis of normal autologous lymphoid cells.
Discussion
Considerable progress has been made toward the development of BsmAbs as therapeutic agents for human cancer (reviewed in reference 9). Human CTLs directed with BsmAb (human residue) in humanized anti-CD3 vl to create v3 resulted in little or no change in the binding efficiency to CTL, suggesting that VL R53 is probably not an essential antigen-binding determinant. The binding efficiency of vl, however, was severely reduced upon the replacement of V, K73 with the human counterpart, Asp, in FR3 to make v2. Further reduction of the binding to CTLs was observed when V~ R53 in v2 was replaced by Ser to create v4, whose binding capacity to CTLs was almost completely abolished. Given the fact that VH K73 is outside of the CDRs, these results imply that contact between selected amino acid residues in FRs with other residues in adjacent CDRs or direct interaction with antigen can influence the antigen-binding efficiency and specificity of the hypervariable loops (11, 36) . However, additional amino acid replacements are required to determine whether murine residue V. K73 is an important binding determinant or whether the human residue D73 compromises binding. Nevertheless, these data demonstrate that amino acid residues outside CDRs should be considered in mAb humanization. Additional amino acid replacements are currently being installed in the humanized anti-CD3 Fab' in an effort to improve its binding efficiency. A three-dimensional molecular model of the humanized (vl) anti-CD3 arm VL and V~ domains is presented (Fig. 2) , illustrating the side chains of residues that differ between murine and humanized versions of anti-CD3 arm. This figure shows that V. K73 in FR3 is located in a loop proximal to CDRs H1 and H2. The fact that a number of adenocarcinomas are characterized by an overexpression of p185 u~R2 presents a unique opportunity for testing the feasibility as well as the efficacy of targeted tumor immunotherapy whereby patients CTLs can be redirected with BsmAb for tumor killing. Fully humanized BsF(ab')2 fragments are shown here to be effective mediators of human breast tumor target lysis in vitro at pharmacologically relevant concentrations. We are currently investigating whether these molecules may be capable of targeting breast tumor cells in vivo for destruction by CTLs. The fact that these molecules are fully humanized and, therefore, less likely to elicit an immune response in cancer patients further advances their potential use in targeted immunotherapy. Importantly, the BsF(ab')2 molecules failed to mediate the killing of normal lymphoid cells (PHA-blasts) or even tumor cells expressing only low to moderate levels of p185 uEaz. The mechanism(s) by which CTLs cause the lysis of tumor targets are not known. However, it has been reported that the cytolytic activity is induced by the binding of antibodytarget conjugates to specific receptors on the effector cell surface (6) . One view proposes that the crosslinking by BsmAbs between clusters of receptors on tumor targets and triggering structures on immune effector cells can induce the release of effector cytolytic substances including cytolysin which may contribute to target killing (8) . Crosslinking may also activate T cells for production of cytokines, e.g., TNF-o~ and IFN-% both of which can exert cytotoxic effects on tumor cells in vitro. The data in this report are consistent with the crucial requirement for crosslinking in order to trigger effector killing of tumor target. Thus two of the BsF(ab')2 variants, v2 and v4, shown to be perfectly capable of binding to target cells but not to effector CTLs, failed to direct tumor killing in the cytotoxicity assay. Further, the presence of p185 uraz ECD, which is shown to block BsF(ab')2 binding to the target, caused a marked inhibition of directed CTL killing of tumor targets.
Our E. coli Fab' expression system in combination with directed chemical coupling as described here has proven effective in the production of clinically relevant quantities of ~nc-tional humanized antibody fragments. The availability of purified material should facilitate the imtiation of clinical studies to evaluate the efficacy of BsF(ab')2 in redirecting CTL killing of tumor cells. It should be noted that the use of F(ab')2 fragments should permit for a more efficient tissue penetration in vivo (37) . The systems used here also allow for replacements of amino acid residues in CDRs and FRs making it possible to study structure-function relationships among the different variant Ab fragments.
Collectively, the data presented here demonstrate the feasibility of producing genetically engineered fi~lly humanized BsF(ab')2 shown to be biologically active in two different in vitro assays. The expression systems described can be applied efficiently for the production of Fab' molecules with selected specificities, and offer an opportunity for understanding the structure-function relationship among the produced Ab fragments. These and similar studies will advance the potential use of BsmAbs in targeted immunotherapy of cancer in humans.
